Kadcyla is both. It’s an antibody-drug conjugate (ADC), a hybrid that combines a targeted antibody with a potent chemotherapy drug into a single molecule. The antibody component seeks out cancer cells, and the chemotherapy component kills them once inside. This puts Kadcyla in its own category, distinct from traditional chemotherapy and from immunotherapy drugs like checkpoint inhibitors.
What an Antibody-Drug Conjugate Actually Is
Kadcyla (the brand name for ado-trastuzumab emtansine, sometimes called T-DM1) has three parts physically linked together. The first is trastuzumab, the same monoclonal antibody found in Herceptin, which locks onto a protein called HER2 on the surface of certain breast cancer cells. The second is DM1, a cell-killing chemical that destroys a cell’s internal scaffolding so it can’t divide. The third is a chemical linker that holds the antibody and DM1 together while the drug travels through the bloodstream.
Think of it as a guided missile. The antibody is the guidance system, steering the drug toward cells that overexpress HER2. The chemotherapy payload is the warhead, released only after the drug enters the cancer cell. This design means the chemotherapy component mostly reaches cancer cells rather than healthy tissue, which is why the side effect profile looks different from standard chemo.
How It Differs From Traditional Chemotherapy
Traditional chemotherapy drugs circulate throughout the body and attack any rapidly dividing cell, cancerous or not. That’s why conventional chemo causes widespread side effects like hair loss and nerve damage. Kadcyla still delivers a chemotherapy agent, but because DM1 is bound to the antibody, it stays largely inactive until it reaches a HER2-positive cell.
Once trastuzumab binds to HER2 on a cancer cell’s surface, the entire complex gets pulled inside the cell. The cell’s recycling machinery breaks down the antibody and linker, releasing DM1 into the cell’s interior. There, DM1 disrupts the structures the cell needs to divide, triggering cell death. This targeted delivery is what separates Kadcyla from a standard IV chemotherapy regimen.
The difference shows up clearly in side effect rates. In a clinical trial comparing Kadcyla to a traditional combination of Herceptin plus a taxane chemotherapy, hair loss occurred in about 60% of women on the standard regimen but only 7% of women on Kadcyla alone. Peripheral neuropathy, the tingling and numbness in hands and feet common with chemo, dropped from 28% to about 13%. Kadcyla does have its own notable side effects, particularly elevated liver enzymes, low platelet counts, and low red blood cell counts, but the overall burden of side effects tends to be lighter.
How It Differs From Immunotherapy
When most people say “immunotherapy,” they’re referring to checkpoint inhibitors, drugs that unleash the body’s own immune system to recognize and attack cancer. These work by blocking proteins (like PD-1, PD-L1, or CTLA-4) that cancer cells use to hide from T cells. By removing that disguise, checkpoint inhibitors allow the immune system to do the killing.
Kadcyla doesn’t work this way. It doesn’t activate or redirect T cells. It doesn’t teach the immune system to recognize cancer. The antibody in Kadcyla does come from immune system technology (monoclonal antibodies are engineered versions of the antibodies your body naturally makes), which is why some people call it immunotherapy. But its primary killing mechanism is chemical, not immunological. The antibody serves as a delivery vehicle, not an immune activator. Some oncologists classify ADCs as “targeted therapy” to distinguish them from both conventional chemo and true immunotherapy.
What Kadcyla Treats
Kadcyla is FDA-approved for two situations, both involving HER2-positive breast cancer. The first is metastatic breast cancer in patients who have already been treated with Herceptin and a taxane chemotherapy. The second is early-stage breast cancer when a patient has gone through pre-surgery treatment with Herceptin and a taxane but still has cancer remaining at the time of surgery.
That second use, in early breast cancer, is backed by the KATHERINE trial, which showed a meaningful benefit. Among patients who switched to Kadcyla after incomplete response to pre-surgery treatment, 88.3% were free of invasive disease at three years, compared to 77% of those who continued on Herceptin alone. That 11-point improvement cut the risk of cancer returning roughly in half. Your tumor must test positive for HER2 overexpression or gene amplification before Kadcyla is an option; an FDA-approved companion diagnostic test is used to confirm this.
What Treatment Looks Like
Kadcyla is given as an intravenous infusion once every three weeks. For early breast cancer, treatment typically continues for 14 cycles (about 10 months). For metastatic disease, it continues until the cancer progresses or side effects become unmanageable.
Because the chemotherapy payload is targeted rather than systemic, many patients find Kadcyla more tolerable day-to-day than traditional chemo. You’re less likely to lose your hair or develop severe nausea. The side effects that do occur tend to involve the liver and blood counts, so expect regular blood draws throughout treatment. Low platelet counts can increase bruising or bleeding risk, and liver enzyme changes may require dose adjustments or treatment pauses.
The Short Answer
Kadcyla is a targeted therapy that contains elements of both worlds. It uses an antibody (borrowed from immune system science) to deliver a chemotherapy drug (DM1) directly into cancer cells. It’s most accurately called an antibody-drug conjugate. If you’re trying to understand where it falls on the spectrum: it kills cancer like chemotherapy, but it finds cancer like a targeted antibody. It does not activate the immune system the way checkpoint inhibitor immunotherapy does.